Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46,239,275
-
Total 13F shares
-
625,623
-
Share change
-
-376,121
-
Total reported value
-
$9,384,727
-
Put/Call ratio
-
78%
-
Price per share
-
$15.00
-
Number of holders
-
9
-
Value change
-
-$5,641,796
-
Number of buys
-
1
-
Number of sells
-
17
Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q1 2024
As of 31 Mar 2024,
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) was held by
9 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
625,623 shares.
The largest 10 holders included
MORGAN STANLEY, CITADEL ADVISORS LLC, Bank of New York Mellon Corp, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, JPMORGAN CHASE & CO, DEUTSCHE BANK AG\, Royal Bank of Canada, NEW YORK STATE COMMON RETIREMENT FUND, Legal & General Group Plc, and Daiwa Securities Group Inc..
This page lists
11
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.